Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink

Abstract

BackgroundTo address a current paucity of European data, this study developed equations to predict risks of mortality, major adverse cardiac events (MACE) and renin angiotensin-aldosterone system inhibitor (RAASi) discontinuation using time-varying serum potassium and other covariates, in a UK cohort of chronic kidney disease (CKD) patients.MethodsThis was a retrospective observational study of adult CKD patients listed on the Clinical Practice Research Datalink, with a first record of CKD (stage 3a–5, pre-dialysis) between 2006 and 2015. Patients with heart failure at index were excluded. Risk equations developed using Poisson Generalized Estimating Equations were utilised to estimate adjusted incident rate ratios (IRRs) between serum potassium and adverse outcomes, and identify other predictive clinical factors.ResultsAmong 191,964 eligible CKD patients, 86,691 (45.16%), 30,629 (15.96%) and 9440 (4.92%) experienced at least one hyperkalaemia episode, when defined using serum potassium concentrations 5.0–< 5.5 mmol/L, 5.5–< 6.0 mmol/L and ≥ 6.0 mmol/L, respectively. Relative to the reference category (4.5 to < 5.0 mmol/L), adjusted IRRs for mortality and MACE exhibited U-shaped associations with serum potassium, with age being the most important predictor of both outcomes (P < 0.0001). A J-shaped association between serum potassium and RAASi discontinuation was observed; estimated glomerular filtration rate was most predictive of RAASi discontinuation (P < 0.0001).ConclusionsHyperkalaemia was associated with increased mortality and RAASi discontinuation risk. These risk equations represent a valuable tool to predict clinical outcomes among CKD patients; and identify those likely to benefit from strategies that treat hyperkalaemia, prevent RAASi discontinuation, and effectively manage serum potassium levels.Electronic supplementary materialThe online version of this article (10.1186/s12882-018-1007-1) contains supplementary material, which is available to authorized users.

Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

“…Notwithstanding the validity of this approach, a prognosticbased definition 203 would convey the graded association with adverse events: risk increases continuously with higher potassium concentrations, and CKD modifies both the distribution of potassium concentration 103 and the associated risk. 169,[204][205][206][207] Incorporating risk factors 103,126,204 into prediction models may help achieve better individual risk stratification. 168,208 There is no consensus on the magnitude, duration, and frequency of elevated potassium values that define chronicity.…”

Impact of Dietary Potassium Restrictions in CKD on Clinical Outcomes: Benefits of a Plant-Based Diet

“… 5 Both hyper- and hypokalemia are associated with adverse clinical outcomes, with a U-shaped association observed between serum potassium level and risk for mortality or major adverse cardiac events in patients with CKD. 6 Interestingly, newer data suggest that patients with advanced CKD may have increased tolerance to elevated serum potassium levels. Specifically, data suggest that 90-day mortality rates with out-of-range plasma potassium concentrations (normal range, 3.5-5.0 mEq/L) are reduced among patients with stages 4-5 CKD versus those with stages 1-2 CKD.…”

Supplementation of Short-Chain Fatty Acid, Sodium Propionate, in Patients on Maintenance Hemodialysis: Beneficial Effects on Inflammatory Parameters and Gut-Derived Uremic Toxins, A Pilot Study (PLAN Study)

“…However, in ESRD, consumption of a fiber-rich diet is a risk factor for hyperkalemia, especially in oliguric and anuric dialysis patients. Therefore, they are advised to consume less vegetables and fruits [ 37 , 38 ]. In addition, the frequent antibiotic therapy [ 39 ] and iron supplementation modulate the microbiome [ 40 ].…”